Trial reportJournal of cosmetic dermatology2025
A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial for the Efficacy and Safety of a Novel Nutraceutical for Mild-to-Moderate Acne.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06097871 (A Double-Blinded, Randomized Control Evaluation of the Efficacy of an Oral Acne Supplement for Adult Women), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-Blinded, Randomized Control Evaluation of the Efficacy of an Oral Acne Supplement for Adult Women
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcne is a prevalent skin concern that has many therapies targeting the pilosebaceous unit. Data suggest there are underlying immuno-inflammatory drivers contributing to acne, with evidence for the efficacy of nutraceuticals including botanicals in targeting the key root causes. However, well-designed clinical studies on their efficacy and safety remain scarce.
aimsThe goal of this study is to determine the safety and efficacy of a novel oral nutraceutical in women with mild to moderate non-nodulocystic acne.
methodsThis 12-week randomized, double-blind, placebo-controlled trial evaluated the safety and efficacy of a nutraceutical addressing mild-to-moderate acne in adult women. Subjects were washed out of all acne products and provided with a standardized skin regimen and randomized into active or placebo groups. The primary endpoint was the change in Investigator Global Assessment (IGA) of acne severity at week 12. Additional endpoints included improvements in inflammatory and non-inflammatory lesion counts and blinded investigator skin assessments.
resultsA total of 102 women were enrolled in the study, with 92 subjects completing the study (47 active; 45 placebo). Compared to placebo, subjects taking the supplement along with the same standardized skin care regimen saw significant improvements in IGA scores, and a higher percentage of them achieved clear/almost clear ratings. There were also significant decreases in both inflammatory and non-inflammatory lesions compared to baseline, and overall skin parameters significantly improved compared to placebo.
conclusionThe oral nutraceutical significantly improves mild-to-moderate acne and overall skin health in adult women when compared to a placebo.
trial registrationClinicaltrials.gov identifier: NCT06097871.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.